RAS is the most commonly mutated driver of tumorigenesis, seen in about 30% of all cancer
cases. There is a subset of tumors termed RAS-driven cancers in which RAS mutation or …

Ras proteins are key elements in the regulation of cellular proliferation, differentiation and
survival. Mutational activation of Ras or of components of its effector pathways are detected …

Mutationally activated and oncogenic versions of the ras genes were first identified in human
tumors in 1982. This discovery prompted great interest in the development of anti-Ras …

RAS was identified as a human oncogene in the early 1980s and subsequently found to be
mutated in nearly 30% of all human cancers. More importantly, RAS plays a central role in …

Introduction: The Ras proteins (K-Ras, N-Ras, and H-Ras) are GTPases that function as
molecular switches for a variety of critical cellular activities and their function is tightly and …

Publisher Summary Several recent research observations have rekindled interest in
targeting Ras for cancer treatment. Genome-wide cancer genome studies have revealed …

The Ras GTPase proteins and their downstream effectors regulate specific intracellular
signalling pathways involved in numerous biological processes. Their actions directly …

Ras is the most frequently mutated oncogene in human malignancies (30 {%}) and is
associated most strongly with the development of neoplasms in which therapeutic …

Ras proteins play a major role in human cancers but have not yielded to therapeutic attack.
Ras-driven cancers are among the most difficult to treat and often excluded from therapies …

Despite more than three decades of intensive effort, no effective pharmacological inhibitors
of the RAS oncoproteins have reached the clinic, prompting the widely held perception that …